BR0100558A - Composições e métodos para tratar a osteoporose - Google Patents
Composições e métodos para tratar a osteoporoseInfo
- Publication number
- BR0100558A BR0100558A BR0100558-8A BR0100558A BR0100558A BR 0100558 A BR0100558 A BR 0100558A BR 0100558 A BR0100558 A BR 0100558A BR 0100558 A BR0100558 A BR 0100558A
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- compositions
- treating osteoporosis
- active ingredient
- carrier
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Abstract
Patente de Invenção: <B>"COMPOSIçõES E MéTODOS PARA TRATAR A OSTEOPOROSE"<D>. A presente invenção refere-se a métodos, composições farmacêuticas e kits úteis para a promoção da formação de massa óssea e/ou a prevenção da perda da mesma e/ou o tratamento da aterosclerose. As composições incluem um polifosfonato como primeiro ingrediente ativo e uma estatina como segundo ingrediente ativo, além de um veículo, carreador ou diluente farmaceuticamente aceitável.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18271300P | 2000-02-15 | 2000-02-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0100558A true BR0100558A (pt) | 2001-09-11 |
Family
ID=22669683
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0100558-8A BR0100558A (pt) | 2000-02-15 | 2001-02-15 | Composições e métodos para tratar a osteoporose |
Country Status (5)
Country | Link |
---|---|
US (1) | US20010036936A1 (pt) |
EP (1) | EP1127573A1 (pt) |
JP (1) | JP2001253827A (pt) |
BR (1) | BR0100558A (pt) |
CA (1) | CA2337381A1 (pt) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2347330C (en) * | 2001-05-10 | 2002-03-12 | Pharmaceutical Partners Of Canada Inc. | Liquid injectable formulation of disodium pamidronate |
JP2002370982A (ja) * | 2001-06-12 | 2002-12-24 | Kowa Co | 骨形成促進剤 |
US20050070504A1 (en) * | 2001-12-21 | 2005-03-31 | The Procter & Gamble Co. | Risedronate compositions and their methods of use |
AU2003211022A1 (en) | 2002-02-19 | 2003-09-09 | Ilex Products, Inc. | Aminodiphosphonate apolipoprotein e modulators |
US7488496B2 (en) | 2002-03-06 | 2009-02-10 | Christer Rosen | Effervescent compositions comprising bisphosphonates and methods related thereto |
ES2448501T3 (es) | 2002-03-06 | 2014-03-14 | Effrx Pharmaceuticals Sa | Composiciones efervescentes que comprenden bisfosfonatos |
KR20030075715A (ko) * | 2002-03-20 | 2003-09-26 | 학교법인 경희대학교 | 성장촉진활성을 갖는 로바스타틴, 이를 포함하는 약제학적조성물 및 이의 사용방법 |
BR0308901A (pt) * | 2002-05-10 | 2005-01-04 | Hoffmann La Roche | ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose |
US20040043072A1 (en) * | 2002-09-04 | 2004-03-04 | Will Joanne Patricia | Alleviation of upper gastrointestinal irritation |
WO2004035060A1 (en) * | 2002-10-15 | 2004-04-29 | Novartis Ag | Bisphosphonates for the treatment of antheroscleorosis and devices comprising them |
GB0327742D0 (en) * | 2003-11-28 | 2003-12-31 | Isis Innovation | Novel uses of known drugs |
US8263137B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US8202546B2 (en) | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US7901710B2 (en) | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US7998500B2 (en) | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US20080176787A1 (en) * | 2005-09-06 | 2008-07-24 | Paul Morley | Parathyroid hormone analogues and methods of use |
US20110046059A1 (en) * | 2005-09-06 | 2011-02-24 | Zelos Therapeutics, Inc. | Pharmaceutically acceptable formulations/compositions for peptidyl drugs |
ITMI20052515A1 (it) * | 2005-12-29 | 2007-06-30 | Abiogen Pharma Spa | Formulazione farmaceutica per il trattamento della osteoartrite |
EP1996118A4 (en) * | 2006-03-07 | 2013-03-06 | Osteoscreen Ip Llc | STRENGTHENING BONES AND CARTILES BY HMG-CO-A REDUCTASE INHIBITOR |
FR2903312B1 (fr) | 2006-07-05 | 2008-09-26 | Univ Aix Marseille Ii | Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament |
JP2010510194A (ja) * | 2006-11-17 | 2010-04-02 | ベシンズ・ヘルスケアー | ビスホスホネート化合物を含む薬剤組成物 |
CN102698276B (zh) | 2008-01-03 | 2014-12-10 | 艾克斯-马赛大学 | 抗hiv治疗期间使用的组合物和方法 |
FR2926020B1 (fr) * | 2008-01-03 | 2010-08-13 | Univ Aix Marseille Ii | Composition cosmetique et/ou dermatologique |
WO2010014184A1 (en) * | 2008-07-28 | 2010-02-04 | Svip1 Llc | Parenteral treatment with statins |
US20110293740A1 (en) * | 2010-05-26 | 2011-12-01 | Baucom Karan Y | Treatment system and method for osteopenia and osteoporosis using non-synthetic bio-available compounds |
EP2749285B1 (en) | 2011-08-26 | 2016-11-02 | National University Corporation Nagoya University | Osteogenesis promoter and use thereof |
US8802658B2 (en) | 2012-05-14 | 2014-08-12 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
ES2661376T3 (es) * | 2012-09-05 | 2018-03-28 | Compass Minerals America Inc. | Métodos y composiciones para evitar el apelmazamiento del cloruro de sodio y evitar las manchas de metales de transición |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993013801A1 (en) * | 1992-01-17 | 1993-07-22 | The Procter & Gamble Company | Treatment for atherosclerosis |
EP1061917A1 (en) * | 1998-03-13 | 2000-12-27 | Merck & Co., Inc. | Methods of inhibiting bone resorption |
-
2001
- 2001-02-09 JP JP2001033011A patent/JP2001253827A/ja active Pending
- 2001-02-13 US US09/782,433 patent/US20010036936A1/en not_active Abandoned
- 2001-02-13 EP EP01301276A patent/EP1127573A1/en not_active Withdrawn
- 2001-02-15 CA CA002337381A patent/CA2337381A1/en not_active Abandoned
- 2001-02-15 BR BR0100558-8A patent/BR0100558A/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1127573A1 (en) | 2001-08-29 |
JP2001253827A (ja) | 2001-09-18 |
CA2337381A1 (en) | 2001-08-15 |
US20010036936A1 (en) | 2001-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0100558A (pt) | Composições e métodos para tratar a osteoporose | |
ATE500218T1 (de) | Mittel zur behandlung von erkrankungen, die mit knochenschwund einhergehen, mit ep4-agonist als wirkstoff | |
BR0308901A (pt) | ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose | |
BR0211888A (pt) | Materiais e métodos para promoção de reparo de tecido nervoso | |
BRPI0408681A (pt) | compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos | |
MXPA02005173A (es) | Composicion farmaceutica para el tratamiento de enfermedades asociadas con disminucion de masa osea. | |
SE9803710D0 (sv) | Use of certain drugs for treating nerve root injury | |
BR0309875A (pt) | métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto | |
SE9901272D0 (sv) | New improved formulation | |
RS50091B (sr) | Upotreba retigabina u lečenju neuropatskog bola | |
BR0207760A (pt) | Composição farmacêutica, uso da mesma, métodos para o tratamento de dor e de inflamação, e, processo para a preparação de uma composição | |
BRPI0507628A (pt) | composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto | |
DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
BR0210122A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo | |
BR0000003A (pt) | Azalidas e métodos de preparação das mesmas | |
CY1109661T1 (el) | 5-cnac ως παραγοντας για χορηγηση απο το στομα τμηματων παραθορμονης | |
BR0105457A (pt) | Combinações terapêuticas para estimulação do crescimento ósseo | |
BR9708114A (pt) | Análogos xantona para o tratamento de doenças infecciosas. | |
TR200000349T2 (tr) | Fizyolojik olarak kabul edilebilir vanadyum bileşimlerinin, tuzlarının ve komplekslerinin kullanımı. | |
ES2194677T3 (es) | Suspensiones de trovafloxacina de administracion por via oral. | |
BR0115424A (pt) | Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, para prevenir a doença de alzheimer, e para inibir o progresso da doença de alzheimer, processos para preparar o composto, e para preparar lactamas, e, uso do composto | |
RU2001124802A (ru) | Применение саредутанта и его фармацевтически приемлемых солей для приготовления лекарственных средств, применяемых для лечения или предупреждения расстройств настроения, расстройств адаптации или смешанных тревожно-депрессивных расстройств | |
JP2002542281A5 (pt) | ||
ATE253359T1 (de) | Antithrombotische mittel | |
DE69917005D1 (de) | Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008. |